David McIntosh: The Evolving Safety Framework for Plasma-Derived Therapies
David McIntosh, Founder and Chair of United Plasma Action, shared Plasma Protein Therapeutics Association’s post on LinkedIn:
“This interesting piece of work will be of significant interest to anyone working in, or interested in, this field of life-saving medicines.
A footnote to add is that what is being described is the 80 percent of current World supplies of plasma that are achieved via Voluntary Reasonably Compensated Donation (VRCD).
Plasma obtained via so-called ‘Unpaid Donation’ almost certainly generates similar results, but as there is so much less of it in the World, relevant data is more scarce.
What is certainly clear, from the vast body of evidence gathered throughout the years of this Century, is that VRCD plasma collection is as safe as, if not safer than, unpaid donor plasma.
As safe – and much more of it – is surely a winning formula!”
Plasma Protein Therapeutics Association (PPTA) shared a post on LinkedIn about a recent article by Halide Tuna et al, published in Annals of Blood, adding:
“A new peer-reviewed publication authored by PPTA’s Halide Tuna and Dr. Toby Simon explores how plasma-derived medicinal products have achieved today’s strong safety profile.
The publication in Annals of Blood highlights the evolution of the ‘safety tripod’ — donor screening, testing, and pathogen reduction — and its role in ensuring the continued safety of plasma-derived therapies.
The conclusion is clear: strong, science-driven systems continue to protect patients today, while ongoing surveillance, periodic evaluation of methods, and technological innovations are essential for future preparedness.”
Title: Plasma-derived medicinal products: a narrative review of the multi-layered approach to ensuring pathogen safety
Authors: Halide Tuna, Toby Simon
Other posts featuring David McIntosh on Hemostasis Today.
-
Jun 23, 2026, 18:27Advancing Gene Therapy Research for Glanzmann Thrombasthenia – Glanzmann’s Research Foundation
-
Jun 23, 2026, 18:17What Every ITP Patient Wants to Know – ITP Support Association
-
Jun 23, 2026, 18:13Ahsan Fareed: Exploring Heart Failure Readmissions in Iron Deficiency Anemia
-
Jun 23, 2026, 18:09Swarnava Roy: Key Findings on Stress Erythropoiesis and Mitochondrial Retention in RBCs
-
Jun 23, 2026, 17:40Hossam El Benawi: How do We Predict Recurrence Post LVT Resoultion?
-
Jun 23, 2026, 17:39Nicolas Gendron: Do We Really Need All These Hemostasis Tests in Patients on DOACs?
-
Jun 23, 2026, 17:33Maité Mulkers: Time is Brain, and One Reason is That a Thrombus Develops Over Time
-
Jun 23, 2026, 17:32Dhargam Aljebouri: Honoured to Be Part of the Young Professionals Breakfast at ISBT 2026
-
Jun 23, 2026, 17:27Dianne E. van der Wal: Phenotype and Activation of the Endothelium in ET at ISTH 2026